Probiotic Supplementation for Diabetic Macular Edema

DG
Overseen ByDemetrios G. Vavvas, MD PhD
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Massachusetts Eye and Ear Infirmary
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores how the probiotic supplement Lactobacillus plantarum 299v might benefit individuals with diabetic macular edema (DME), a condition that can impair vision due to fluid buildup in the eye. Researchers aim to determine if taking the supplement twice daily for four months can reduce eye swelling, improve eyesight, and decrease the need for other treatments like eye injections. Participants must have DME and no issues with probiotics, such as allergies or stomach problems. Those with DME and no prior problems with probiotics might consider joining this study. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of people.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is there any evidence suggesting that this treatment is likely to be safe for humans?

Research has shown that Lactobacillus plantarum 299v, the probiotic being tested, is safe for use. The FDA has granted it Generally Recognized as Safe (GRAS) status, indicating it is widely accepted as safe to consume.

In earlier studies, no major reports of serious side effects have emerged. However, individuals with allergies or digestive issues related to probiotics should exercise caution. Taken orally, most people tolerate this supplement well. If side effects occur, they are usually mild, such as an upset stomach.

Overall, evidence suggests that Lactobacillus plantarum 299v is well-tolerated, making it a promising option for those considering joining this trial.12345

Why do researchers think this study treatment might be promising for diabetic macular edema?

Unlike the standard treatments for diabetic macular edema, which often involve injections or laser therapy to reduce swelling and prevent vision loss, Lactiplantibacillus plantarum 299v is a probiotic supplement taken orally. This makes it a non-invasive option with potentially fewer side effects. Researchers are excited because it offers a new approach by potentially modulating gut microbiota to influence inflammation and immune response in the eyes, which is a novel mechanism in treating this condition.

What evidence suggests that this probiotic supplement could be effective for diabetic macular edema?

Research has shown that Lactobacillus plantarum 299v, a type of probiotic, may be beneficial in several health areas. While direct evidence on its effects on diabetic macular edema (DME) is limited, this probiotic is known to reduce inflammation. Reducing inflammation might aid in managing DME, which involves swelling in the eye. Some studies suggest it also improves gut health, potentially benefiting eye health indirectly. However, the specific effects on eye swelling or vision clarity in DME patients remain under investigation. In this trial, all participants will receive Lactobacillus plantarum 299v supplementation to further explore its potential benefits for DME.13567

Are You a Good Fit for This Trial?

This trial is for patients with diabetic macular edema, a condition affecting the eye. Participants will be those who can safely consume probiotics and are willing to take Lactobacillus plantarum 299v twice daily for four months. Specific inclusion and exclusion criteria details were not provided.

Inclusion Criteria

I have diabetic macular edema now.
I am 18 years old or older.

Exclusion Criteria

Patients with contraindication to probiotic supplement (e.g. prior allergy or GI intolerance and any type of immunocompromised diseases)

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Lactobacillus plantarum 299v orally twice daily for four months

16 weeks
Monthly visits for monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Lactiplantibacillus Plantarum 299v

Trial Overview

The study tests if the probiotic Lactobacillus plantarum 299v can reduce thickness in the central part of the retina and improve vision over four months compared to past data from patients who didn't receive this supplement.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Main Arm - twice daily for 4 monthsExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Massachusetts Eye and Ear Infirmary

Lead Sponsor

Trials
115
Recruited
15,000+

Citations

Lactiplantibacillus Plantarum 299v Probiotic ...

In this pilot prospective, interventional, longitudinal study, we aim to evaluate the potential benefits of the probiotic supplement Lactobacillus plantarum ...

Lactiplantibacillus Plantarum 299v Probiotic Supplementation ...

The study seeks to address the following questions: Does central macular thickness on optical coherence tomography decrease after 4 months of ...

Lactobacillus plantarum 299v in Diabetic Macular Edema

Outcomes will be compared to a control group, using historic retrospective data. Participants will take Lactobacillus plantarum 299v orally ...

The Health Benefits of Probiotic Lactiplantibacillus plantarum

In particular, L. plantarum strains were reported to produce pro-inflammatory cytokines in the intestinal epithelial cells [25] and reduce kidney stones [26].

Strain-Specific Therapeutic Potential of Lactiplantibacillus ...

L. plantarum 299v [92] did not show significant improvements in clinical outcomes for ICU patients, suggesting that while probiotics may offer benefits in ...

GRAS Notice 685, Lactobacillus plantarum strain 299v

The subject of this Generally Recognized as Safe (GRAS) determination is a strain ofthe probiotic bacterium Lactobacillus plantarum designated ...

Strain-Specific Therapeutic Potential of Lactiplantibacillus ...

This systematically scoping review aims to evaluate the therapeutic potential and clinical benefits of specific Lactiplantibacillus plantarum (L. plantarum) ...